Isomorphic Labs
Isomorphic Labs is an AI drug discovery company founded by Sir Demis Hassabis, building on the Nobel-winning AlphaFold system to develop predictive and generative AI models that…
No open positions right now. Check back soon!
Browse all jobsAbout the company
Isomorphic Labs is an AI drug discovery company founded by Sir Demis Hassabis, building on the Nobel-winning AlphaFold system to develop predictive and generative AI models that accelerate the design of novel medicines. The company's interdisciplinary team of drug discovery experts and machine learning specialists aims to transform drug discovery at digital speed, with a mission to one day solve all disease with the help of AI. As of early 2025, Isomorphic Labs has announced a Series B investment round, indicating significant growth and investor confidence.
Isomorphic Labs currently lists job openings in London, Cambridge (MA), and Lausanne, with no Spain offices mentioned in the provided evidence. The company's work culture emphasizes advancing careers at a company shaping the future, and its roles span machine learning research, engineering, security, and drug design. For international professionals, the company offers opportunities in cutting-edge AI and drug discovery, with positions based primarily in the UK, Switzerland, and the US.
For International Professionals
- Isomorphic Labs was founded by Sir Demis Hassabis, co-founder of Google DeepMind, and builds on the Nobel-winning AlphaFold system.
- The company announced a Series B investment round in February 2025, indicating recent growth and financial backing.
- Current job openings are located in London (UK), Cambridge (MA, USA), and Lausanne (Switzerland), with no Spain offices listed.
- Roles span machine learning research, engineering, security, and drug design, offering opportunities for AI and life sciences professionals.
- The company's mission is to use AI to 'solve all disease', positioning it at the forefront of digital biology.
Company History
Isomorphic Labs was founded by Sir Demis Hassabis, the CEO of Google DeepMind, to apply frontier AI to drug discovery. The company builds on the Nobel-winning AlphaFold system to develop predictive and generative AI models for designing novel molecules and accelerating scientific discovery. In February 2025, Isomorphic Labs announced a Series B investment round.